
==== Front
Dement Neuropsychol
dn
Dementia & Neuropsychologia
1980-5764
2764-4863
Academia Brasileira de Neurologia, Departamento de Neurologia Cognitiva e Envelhecimento

10.1590/1980-5764-DN-2023-0116
00215
View & Review
Vascular cognitive impairment and dementia: a narrative review
Comprometimento cognitivo vascular e demência: uma revisão narrativahttps://orcid.org/0000-0002-0257-3107
Jiménez-Ruiz Amado 1 conceptualization investigation supervision validation writing – original draft writing – review & editing
https://orcid.org/0000-0003-0126-6364
Aguilar-Fuentes Victor 1 investigation writing – original draft writing – review & editing
https://orcid.org/0000-0002-3755-5072
Becerra-Aguiar Naomi Nazareth 1 conceptualization investigation writing – original draft writing – review & editing
https://orcid.org/0000-0003-4139-4045
Roque-Sanchez Ivan 1 investigation writing – original draft
https://orcid.org/0000-0002-0482-7916
Ruiz-Sandoval Jose Luis 1 2 conceptualization supervision validation
1 Stroke & Cerebrovascular Disease Clinic, Hospital Civil Fray Antonio Alcalde, Neurology Department, Guadalajara, Jalisco, Mexico.
2 Universidad de Guadalajara, Centro Universitario de Ciencias de la Salud, Departamento de Neurociencias, Guadalajara, Jalisco, Mexico.
Correspondence: Naomi Nazareth Becerra Aguiar; Email: naomiba2002@gmail.com.
Disclosure: The authors report no conflicts of interest.

23 9 2024
2024
18 e2023011602 12 2023
15 4 2024
09 6 2024
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License
ABSTRACT

Vascular cognitive impairment (VCI) is the second most common cause of cognitive impairment after Alzheimer's disease. The VCI spectrum involves a decline in cognition attributable to vascular pathologies (e.g., large infarcts or hemorrhages, microinfarcts, microbleeds, lacunar infarcts, white matter hyperintensities, and perivascular space dilation). Pathophysiological mechanisms include direct tissue injury, small vessel disease, inflammaging (inflammation + aging), atrophy, and altered neurotransmission. VCI is diagnosed using distinct clinical and radiological criteria. It may lead to long-term disability and reduced quality of life. An essential factor for reducing cognitive impairment incidence is preventing stroke by managing traditional and non-traditional cerebrovascular risk factors. This article reviews the spectrum of VCI, epidemiology, risk factors, pathophysiology, diagnosis, available treatment, and preventive strategies.

RESUMO

O comprometimento cognitivo vascular (CCV) é a segunda causa mais comum de comprometimento cognitivo depois da doença de Alzheimer. O espectro do CCV envolve um declínio na cognição atribuível a patologias vasculares (por exemplo, grandes infartos ou hemorragias, microinfartos, micro-hemorragias, infartos lacunares, hiperintensidades da substância branca e dilatação do espaço perivascular). Os mecanismos fisiopatológicos incluem lesão tecidual direta, doença de pequenos vasos, inflammaging (inflamação+envelhecimento), atrofia e neurotransmissão alterada. O CCV é diagnosticado usando critérios clínicos e radiológicos distintos. Pode levar à incapacidade a longo prazo e à redução da qualidade de vida. Um fator essencial para reduzir a incidência de comprometimento cognitivo é prevenir o acidente vascular cerebral através do manejo dos fatores de risco cerebrovasculares tradicionais e não tradicionais. Este artigo revisa o espectro do CCV, epidemiologia, fatores de risco, fisiopatologia, diagnóstico, tratamento disponível e estratégias preventivas.

Keywords:

Vascular Dementia
Cognition Disorders
Dementia
Cerebrovascular Diseases
Stroke
Palavras-chave:

Demência Vascular
Transtornos Cognitivos
Demência
Transtornos Cerebrovasculares
Acidente Vascular Cerebral
==== Body
pmcINTRODUCTION

Cognition is one of the primary brain functions and plays a vital role in the aging process. Cognitive impairment leads to increased dependency and decreased quality of life throughout the lifespan. Assuring adequate cognition and acknowledging its detrimental factors, such as cardiovascular diseases, may prevent cognitive impairment and lead to a healthier lifestyle and better brain health 1 .

Acquiring, processing, storing, and retrieving information by the brain refers to normal cognition composed of memory, executive functioning, perception, attention, motor movement, and language skills 2 . An impairment in cognition is classified into a spectrum of disorders ranging from mild to severe, including age-related cognitive decline, mild cognitive impairment, and major cognitive impairment 3 .

According to the Diagnostic and Statistical Manual of Mental Disorders fifth edition (DSM-V), mild neurocognitive disorder refers to a decline in one or more cognitive domains (executive function, learning, memory, complex attention, language, social cognition, and perceptual-motor) without interfering with independence in everyday activities. Major neurocognitive disorder (previously known as dementia) involves cognitive deficits that interfere with independence in daily activities. Both conditions can be further classified according to etiology (Alzheimer's disease, frontotemporal lobar degeneration, Lewy body dementia, Parkinson's disease, vascular, and related, among others). The second most common cause of neurocognitive disorder is vascular in origin, a condition known as vascular cognitive impairment (VCI) 4 .

VCI refers to cognitive decline attributable to cerebrovascular disease, including all forms of stroke. Recent developments have changed our understanding of this complex syndrome affecting millions of individuals worldwide. Here, we briefly review the currently available evidence and explore the associated challenges with diagnosis and treatment.

THE SPECTRUM OF VASCULAR COGNITIVE IMPAIRMENT

VCI involves a spectrum of vascular brain pathologies contributing to any degree of cognitive impairment 5,6 . According to the Vascular Impairment of Cognition Classification Consensus Study phase 2 (VICCCS-2), VCI can be classified into mild VCI (VaMCI) or major VCI (vascular dementia, VaD) depending on the severity and the compromise of the ability to perform activities of daily living. VaD is further subclassified as poststroke dementia, subcortical ischemic vascular dementia, multi-infarct dementia, and mixed dementia 7 . Classification criteria will be further discussed.

EPIDEMIOLOGY OF COGNITIVE IMPAIRMENT

MCI is a syndrome in which patients have cognitive decline with minimal impairment in their activities of daily living. Its prevalence varies according to age, ranging from 6.7% for individuals aged 60–64 years to 25.2% for those aged 80–84 8 . The incidence increases with age, and more than half of individuals with MCI progress to dementia within five years after diagnosis 9 . MCI prevalence varies according to the population and risk factors. Depression, diabetes, hypertension, rurality, and low education are associated with increased risk of MCI 10 . In Latin America, it ranges from 6.8 to 25.5%, with a higher prevalence in the oldest, lower-educated adults, women, and rural settings 11,12 .

Approximately 50 million people live with dementia worldwide, estimated to increase to 152 million by 2050. Dementia is decreasing in developed countries but increasing in developing countries. Approximately 66.0% of individuals with dementia live in low- and middle-income countries, but by the year 2050, it is projected to increase to 71.0 or 72.0% 13 . In Brazil, approximately 1.5 million people live with dementia with an estimated prevalence of 17.5% 14 . Over the last years, the burden of dementia has been steadily rising in Brazil, being the second cause of death by 2016 15 . In the Mexican population, the estimated prevalence of dementia is 7.8% for Alzheimer's disease (AD), 4.3% for VaD, and 2.1% for mixed dementia 16 . However, in a clinical-pathological analysis from two longitudinal studies (The Religious Orders Study and the Rush Memory and Aging Project), only 9.0% had AD, whereas 40.0% consisted of AD plus prominent vascular pathologies such as macroscopic infarcts, cerebral amyloid angiopathy, atherosclerosis, or arteriosclerosis 17 . A Mexican cohort study estimating the incidence of cognitive impairment in previously cognitively healthy Mexican individuals revealed that 20.0% of the subjects developed moderate cognitive impairment, of which 10.0% developed severe cognitive impairment during a three-year follow-up 18 . Similarly, Argentina and Venezuela, other Latin American countries, presented a prevalence of dementia of 7.8% and 8.04%, respectively, mostly attributed to physical inactivity, hypertension, obesity, and hearing loss 19-21 .

EPIDEMIOLOGY OF VASCULAR COGNITIVE IMPAIRMENT

The prevalence of VCI has varied across the years due to the different diagnostic criteria and definitions implemented.

VCI is considered the second most common etiology of dementia. A neuropathological study revealed that in a population of 407 individuals with MCI, 23.0% showed a pure vascular neuropathological result, whereas 51.0% had a mixed neuropathological result. In patients with dementia, only 7.0% had a pure vascular neuropathological result, and 70.0% had a mixed neuropathological result 22 .

Post-stroke cognitive impairment (PSCI) is a common cause of long-term disability and reduced quality of life 23 . Previous studies in European populations indicated that in the first year after the stroke, half of the patients may develop some degree of cognitive impairment 24,25 . The incidence of PSCI in Latin America has not been fully addressed. In a Mexican study, PSCI was presented in up to 41.0% of patients 26 . However, a Brazilian study showed contrasting results with a PSCI incidence of 16.8% 27 . The difference may be due to the population included—while the Mexican study considered cerebral venous thrombosis, and both ischemic and hemorrhagic stroke, the Brazilian study focused mainly on non-embolic ischemic stroke patients.

RISK FACTORS OF VASCULAR COGNITIVE IMPAIRMENT

The incidence and prevalence of dementia have decreased in developed countries and increased in developing countries; this phenomenon is mainly attributed to reduced cerebrovascular risk factors, such as hypercholesterolemia and smoking in developed countries, which are highly associated with VCI 13 .

VCI is a stepwise process in which many diseases and sociodemographic conditions may contribute (Figure 1). Some common risk factors for VCI include diabetes mellitus, overweight, obesity, atrial fibrillation, elevated low-density lipoprotein, and aging (especially males >80 years old) 6,28 . Hypertension and depression are strong predictors of possible VaD 29 . Poor social relationships and deficient support networks are also associated with white matter hyperintensity (WMH) progression, another biomarker of cognitive impairment 30 . Individuals with a stroke have a 9-fold increased risk of developing cognitive impairment in the first year after the event 31 . This risk increases with recurrent strokes 32 .

Figure 1 The spectrum of vascular cognitive impairment. Progression and features in different stages of cognitive decline.

Approximately 40.0% of dementia risk factors are potentially modifiable, most related to cardiovascular damage 33 . This means that by preventing cardiovascular and metabolic diseases, many dementia cases may be preventable. Sposato et al. proposed, from a retrospective analysis of the incidence rate of dementia and stroke from a 10-year Canadian survey, that the reduction in stroke by 32.4% could have contributed to the 7.4% reduction in dementia incidence 34 .

PATHOPHYSIOLOGY

Researchers previously associated cognitive impairment with large vessel arteriosclerosis, a condition known as arteriosclerotic dementia 35 . Although incomplete, this hypothesis was not far from the current mechanisms involved in VCI, making brain hypoperfusion a fundamental pathophysiological mechanism 36 . Nevertheless, arteriosclerosis is not the only process involved in this complex syndrome. Other processes that contribute to VCI presentation are large infarct, lacunar infarct, microinfarct, myelin loss, WMH, cerebral amyloid angiopathy, and perivascular space dilation 37 .

VCI may present in a slow and progressive matter, such as seen in small vessel disease (Figure 2) and multi-infarct dementia (Figures 3A and 3C), or in a sudden matter, such as seen in a large strategic infarct (Figure 3B). Stroke may also trigger cognitive impairment in an already damaged brain (Figure 3D).

Figure 2 An 81-year-old woman with cognitive impairment. Brain magnetic resonance imaging in fluid-attenuated inversion recovery (FLAIR) sequence (axial view) showing subcortical (red arrowhead) and periventricular (orange arrowhead) white matter hyperintensities consistent with small vessel disease. Global brain atrophy is also observed (personal communication).

Figure 3 Distinctive phenotypes of cognitive decline with corresponding vascular pathology. (A) White matter hyperintensities have a slow progression of cognitive decline. (B) Strategic focal lesion has an acute one-step pattern with either some recovery or decline progression depending on the brain resilience. (C) Multi-infarct dementia is consistent with a stepwise pattern of vascular cognitive impairment (VCI). (D) Cerebrovascular disease (CVD) + neurodegenerative (mixed mechanism) may present in two sceneries: the first is an already damaged brain by a degenerative disease that suffered a brain infarction with subsequent cognitive decline; and the second is a one-step pattern that triggers a neurodegenerative process. Cerebral infarcts and white matter disease are shown in white. Amyloid plaques are indicated in orange.

Slowly progressive VCI is usually seen in small vessel disease (SVD). The most common subtype of SVD is cerebral amyloid angiopathy, a condition also associated with intracranial hemorrhage, microbleeds, and microinfarcts. SVD leads to VCI via hypoperfusion, ischemic neuronal injury, and diffuse tissue injury 6 . Subcortical dementia (previously known as Binswanger disease) is a form of SVD associated with damage mainly in the white matter; the injury is conformed by gradual subcortical ischemia and WMH 38,39 .

SVD and subsequent VCI may also be a product of genetic disturbances. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most common cause of genetic SVD; its early identification and management can increase the quality of life in this progressive and irreversible condition 40 . Vascular smooth muscle cell degeneration, seen in CADASIL, results in an impaired muscular layer of brain vessels. This impairment leads to vessel breakdown, fibrosis, and thickening of the vessels with subsequent stenosis, hypoperfusion, and brain infarcts 41 . Genetic causes of SVD present cognitive impairment early in life and are the purest types of VCI.

Aging is another slow and progressive mechanism that stimulates multiple vascular changes, starting with the thinning of large and small blood vessels. A decrease in cerebral blood flow contributes to a reduction in glucose uptake, an increase in collagen accumulation, a rupture of the blood-brain barrier, decreased tight junctions, decreased mitochondrial contents, inflammation, and oxidative damage. These processes contribute to neuron loss and increased susceptibility to cognitive decline 42 .

Large strategically located infarcts mainly cause sudden onset VCI. The most associated locations are the thalamus, the hippocampus, and the dominant hemisphere 6,32,43 . Although strategically located infarcts are highly associated with cognitive impairment, it is essential to know that the manifestation of cognitive impairment also depends on cognitive reserve. This concept will be discussed later on.

Other brain insults leading to VCI are macroscopic hemorrhages, microbleeds, and microinfarcts. Microinfarcts are only observable using microscopy due to their small diameters of 0.2 to 1 mm. Although the mechanism of dementia is still unclear, it may be associated with innate and adaptive immune responses and impaired protein clearance 6 .

An important subtype of VCI is post-stroke dementia (PSD) 44,45 . This condition refers to VaD detected after an ischemic or hemorrhagic stroke. PSD can be further subclassified into early-onset PSD and late-onset PSD. Early-onset PSD is a condition in which cognitive impairment is frequently detected in the first six months after a stroke. It is usually driven by cardiovascular risk factors (hypertension, atrial fibrillation, hyperlipidemia, and diabetes) and stroke lesion characteristics (location and size). Early-onset PSD appearance also depends on brain resilience. Brain resilience, which is constituted by cognitive reserve and brain reserve, refers to the capacity of the brain to resist and recover its regular functions after an insult. More brain resilience is associated with lower odds of developing early-onset PSD. Late-onset PSD affects up to 23.9% of individuals with a previous stroke 32 . The presentation time of this condition is variable but may occur up to eight years after the brain insult 46 , augmenting the need for continuous cognitive screening throughout the lifespan. Late-onset PSD is caused by recurrent strokes, amyloid-beta deposition, and small vessel disease, the last being the most important etiological factor driving this incapacitating disease 32 . Severe WMH is associated with a 7.7-fold increased risk of developing severe cognitive impairment 47 . The amyloid β deposition is known to be related to dementia incidence; however, little is known about the role of ischemia in amyloid β deposition. Cerebral hypoxia reduces the activity of lipoprotein receptor-related protein 1 (LRP1) and boosts the activity of receptor for advanced glycation end products (RAGE), β-secretase, and γ-secretase 36,48 . Thereby, it increases the production and accumulation and decreases the clearance of amyloid β. Amyloid β deposition further decreases brain perfusion by inducing vasoconstriction. Both of these mechanisms work in a vicious cycle that culminates in an elevated risk of developing dementia 49-51 .

Other mechanisms involved in VCI are local and systemic inflammation, neuronal atrophy, oligodendrocyte and astrocyte changes, and altered signaling due to impaired lymphatic clearance of toxins and proteins 6,52 .

CLINICAL MANIFESTATIONS

Typically, patients with VCI have mental slowness and impaired executive function (cognitive flexibility, planning, organizing, inhibition, and self-regulation). Cognitive impairment affecting only executive functions (non-amnestic cognitive impairment) is more frequent in VCI than in AD and can present in up to 49.0% of individuals. However, VCI individuals may also exhibit memory disturbances, especially if there is damage to the medial temporal lobe, in which case, there is a 2.7-fold increased risk of developing amnestic VCI 53 . Increased amyloid β deposition may also contribute to the development of amnestic VCI.

Memory loss and behavioral and psychiatric symptoms, including apathy, anxiety, and depression, are frequent and should also be pursued when evaluating an individual with VCI 6 .

DIAGNOSIS

VCI is a complex term that has evolved over the years. To have a clearer understanding of the concept and its diagnosis, it is essential to quickly recap the evolution of this term.

At first, cognitive impairment was related to large vessel arteriosclerosis (arteriosclerotic dementia). However, this idea was only partially accepted 35 . Later, amyloid plaques were considered as the sole etiology of cognitive impairment (Alzheimerization of dementia). After many years, Hachinski et al. introduced the term "multi-infarct dementia" to refer to individuals with slow and progressive major cognitive impairment, primarily related to cardioembolic causes 54 . This term persists nowadays. Nevertheless, it is known that cardioembolism is not the sole mechanism involved in VCI. Therefore, the National Institute of Neurological Disorders and Stroke (NINDS) and the Association Internationale pour la Recherche et L’Enseignement en Neurosciences (AIREN, International Association for Research and Education in Neuroscience) proposed the diagnostic criteria for VaD to incorporate other etiologies of cognitive impairment related to vascular disease 55,56 .

An inconvenience with these diagnostic criteria was that the cognitive evaluation was mainly focused on memory impairment. Although memory impairment is seen in individuals with VCI, the majority, especially in the early stages, present cognitive impairment mainly in executive functions. PSD is a term that refers to individuals with major cognitive impairment detected after a stroke 44,45 . This definition was greatly accepted and is still used in most reviews. However, this term did not distinguish between pure vascular PSD and mixed PSD. This led to an overdiagnosis of dementia related to cardiovascular diseases, which was corrected with more recent diagnostic criteria 7 .

After many years of studying major cognitive impairment related to vascular diseases, an inconvenience remained: late diagnosis. Individuals with VaD, by definition, already had an established severe impairment in the activities of daily living. Therefore, VCI was introduced to detect individuals with cognitive impairment related to cardiovascular diseases and, if possible, prevent major cognitive dysfunction 57 .

Afterward, other diagnostic criteria were introduced to define minor and major cognitive impairment related to vascular diseases (Figure 4). The most used diagnostic criteria are The American Heart Association/The American Stroke Association (AHA/ASA), which define vascular mild cognitive impairment (VaMCI) and VaD, both subdivided into probable and possible 58,59 ; the DSM-V, which defines minor and major neurocognitive disorder 4 ; The International Society for Vascular Behavioral and Cognitive Disorders (VASCOG), which classifies mild and major vascular cognitive disorders 60,61 ; and the VICCCS-2, which distinguishes between mild VCI and VaD 7 . Some national academies, such as the Brazilian Academy of Neurology, also includes their own criteria with great reliability 62 .

Figure 4 Diagnostic criteria of vascular cognitive impairment. Summary of the proposed diagnostic criteria for vascular cognitive impairment proposed by the National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l’Enseignement en Neurosciences, the American Heart Association/The American Stroke Association; the Diagnostic and Statistical Manual of Mental Disorders fifth edition, the International Society for Vascular Behavioral and Cognitive Disorders, and the Vascular Impairment of Cognition Classification Consensus Study phase 2.

Abbreviations: NINDS, National Institute of Neurological Disorders and Stroke; AIREN, Association Internationale pour la Recherche et l’Enseignement en Neurosciences; AHA, American Heart Association; ASA, American Stroke Association; DSM, Diagnostic and Statistical Manual of Mental Disorders; VASCOG, Vascular Behavioral and Cognitive Disorders; VICCCS, Vascular Impairment of Cognition Classification Consensus Study; ICD, international classification of diseases; CVD, cerebrovascular disease; ADL, activities of daily living; WMH, white matter hyperintensities.

VICCCS-2 diagnostic criteria remain the most suggested for determining VCI. The preferred imaging method for diagnosing cerebrovascular brain injury according to the VICCCS-2 criteria is magnetic resonance imaging (MRI)-based with measures of the number, size, locations of infarcts and hemorrhages, total brain volume (including the hippocampus), and WMH burden 7 .

Mild and major cognitive impairment are the two major subcategories of VCI, according to the VICCCS-2 diagnostic criteria, with the main difference regarding the severe disruption of activities of daily living. Major cognitive impairment is further subdivided into post-stroke dementia (history of stroke and cognitive deficit either immediately after or within six months after the insult and no recovery), subcortical ischemic vascular dementia (small-vessel disease mainly subcortically), multiinfarct (cortical) dementia, and mixed dementias (combination of vascular and degenerative disease) 61 .

Pre-mild VCI or "brain at risk" stage is discussed as a stage previous to cognitive impairment, in which there is no cognitive impairment, but there is evidence of vascular damage, which may be a future VCI risk 63 .

Assessing cognitive impairment in patients with a cerebrovascular etiology is challenging since the cognitive batteries are biased toward AD, and the cognitive domains affected in VCI are different, with a preponderance of executive function. Among the first tools to assess cognitive deficits in patients with cerebrovascular disease is the cognitive impairment harmonization standards created by NINDS - Canadian Stroke Network (NINDS-CSN). The protocols are divided into very short (5 minutes), short (30 minutes), and extensive (1 hour). The tests used include Animal Naming, Trail Making, Rey-Osterrieth Complex, Hopkins Verbal Learning, and Naming Test Recognition, among others 64 . Since then, adaptations to the NINDS-CSN have been proposed such as the transitional and final battery of the Groupe de Réflexion pour l’Evaluation COGnitive VASCulaire (GRECog-Vasc, Reflection Group for Vascular Cognitive Evaluation) adapted for the French population 65 .

Apart from the NINDS-CSN criteria, the most widely validated tools are the Clock Drawing, the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), and the Brief Memory and Executive Test (BMET), tools that have been compared and evaluated in different studies. Results have reported that MoCA applied 3–6 months after a stroke is more sensitive and superior to the NINDS-CSN 5-minute protocol 66,67 . A systematic review evaluating the psychometric properties of cognitive screening instruments in VCI revealed that the MoCA (92.7% sensitivity, and 96.3% specificity) and MMSE (78.0% sensitivity, and 92.0% specificity) had excellent accuracy in differentiating VaD from controls, and the MoCA and BMET had the greatest accuracy in separating mild VCI from controls (sensitivity and specificity of 81.0 and 79.0, and 85.0 and 84.0%, respectively). The study concluded that the MoCA is accurate and reliable for differentiating VaD and mild VCI 67 .

The other aspect of the diagnosis involves establishing the vascular etiology for the cognitive disorder with neuroimaging evidence (preferably with MRI) of large infarcts, lacunar infarcts, WMH, or hemorrhages, as well as a temporal relationship with the decline in cognition accompanied by personality and mood changes, hemiparesis, lower facial weakness, visual field defects, sensory loss, gait disturbance, and urinary symptoms consistent with clinical evidence of cerebrovascular disease 60 .

TREATMENT

The non-pharmacological management of VCI includes dietary interventions and exercise. Several studies suggest the consumption of omega-3 fatty acids, non-fried fish, and the Mediterranean diet to avoid WMH progression and cognitive decline 68 . A randomized controlled trial evaluated the effect of progressive aerobic exercise training on cognitive and executive functions and concluded that the intervention group performed better on cognitive scales 58 . Cheon et al. demonstrated that exercise reduces the risk of developing PSD 69 .

An interventional study evaluating the progression of WMH in people with diabetes using a multidomain approach concluded that lifestyle interventions such as physical activity and diet modifications reduced the WMH burden. However, there were no differences in cognitive function compared to the control group 70 .

The pharmacological treatment of VCI involves cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine, commonly used for AD. According to the AHA/ASA recommendations and recent meta-analyses, donepezil and galantamine have the most significant effect on cognition 59,71 ; however, these results are insufficient to recommend for routine use and are not currently approved by the US Food and Drug Administration. In other studies, rivastigmine showed a slight improvement in executive function and behavior, and memantine resulted in a slight improvement in cognition 72,73 . Another group of drugs that may prevent dementia progression includes anticoagulants 74 . Recent meta-analyses and population-based studies support the hypothesis that anticoagulants (direct oral anticoagulants and vitamin K inhibitors) may prevent cognitive impairment 75-77 . Anecdotal evidence supporting anticoagulant use for preventing dementia progression has been available since 1968 74 .

As mentioned above, atrial fibrillation is related to the development of multiple cardioembolic strokes, making it an important risk factor for the development of VCI. Even though anticoagulation is generally recommended, the choice of anticoagulant is not fully elucidated. A Brazilian randomized clinical trial (GIRAF, CoGnitive Impairment Related to Atrial Fibrillation) evaluated the cognitive outcomes of dabigatran versus warfarin in older patients with atrial fibrillation, revealing no statistically significant difference in changes in cognitive performance between both anticoagulant strategies; therefore, there is no evidence of a beneficial effect of dabigatran 78 .

To avoid stroke recurrence, a strong risk factor for cognitive decline, the AHA/ASA guidelines recommend antihypertensives such as diuretics and angiotensin-converting enzyme inhibitors (ACEi) if blood pressure is ≥140 mmHg systolic or ≥90 mmHg diastolic. Other recommended medications are lipid-lowering drugs, especially statins, antithrombotics, and anticoagulants for cardioembolic stroke or transient ischemic attack 79 . Moreover, treatment to prevent the progression of WMH includes antihypertensives, such as ACEi and angiotensin receptor blockers, statins, and antithrombotics, including antiplatelet drugs like aspirin 68 .

Pharmacological strategies are the cornerstone for treating VCI, but rehabilitation may also improve cognition. A randomized active-controlled clinical trial showed improved global cognitive function and better results in the MoCA test in the group of people with subcortical VCI taking a 7-week computerized cognitive training course; the study also revealed increased functional connectivity between the left dorsolateral prefrontal cortex and medial prefrontal cortex after training 80 . Other cognitive rehabilitation programs have evidenced improvement in specific domains, such as working memory and attention and synchronization of activity in cerebellar areas 81 .

PREVENTION

Hachinski et al. proposed preventing dementia (at least one-third of them) through stroke prevention, according to the Berlin Manifesto. Stroke and dementia are risk factors for each other and share some of the same protective factors, such as the reduced prevalence of smoking, anticoagulation for atrial fibrillation, and systolic blood pressure lower than 140 mmHg 82 .

A retrospective cohort study evaluating the effect of thrombolysis on the incidence of poststroke dementia showed that thrombolysis administration within three hours of the stroke was associated with a decreased rate (24.0% at one year and 21.0% at five years) of developing dementia 83 .

VCI has known modifiable risk factors, and impairment in cognition may be prevented by managing them 84 . Optimal blood pressure, blood glucose, total cholesterol, smoking habits, physical activity, body mass index, healthy diet, and cognitively and socially stimulating activities are metrics for brain health, which are essential for cognition preservation 85 . Although only two of these metrics have strong evidence for prevention-risk patients (hypertension control and physical activity), they are reasonable strategies for overall mortality and vascular disease prevention 59 .

In the Systolic Blood Pressure Intervention Trial — Memory and Cognition in Decreased Hypertension (SPRINT MIND) study, 9,361 older adults with some cardiovascular risk factors but no diabetes, stroke, or dementia were followed up for one year, evaluating progression to mild cognitive impairment and dementia. There was a statistically significant lower rate of mild cognitive impairment progression and non-statistically significant dementia progression in the intensive (<120 mm Hg systolic pressure) vs. the standard treatment group (<140 mm Hg systolic pressure) 86 .

The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) multimodal intervention (diet, exercise, cognitive training, and vascular risk monitoring) provided strong evidence for preventing AD and VCI, and it seems promising as an essential brain health strategy 87 .

New studies are evaluating the effect of oral anticoagulants and vitamin K inhibitors on reducing cognitive decline and dementia risk. There is also interest in a specific group of patients with non-valvular atrial fibrillation. In patients with cerebral small vessel disease, there is evidence of increased bleeding risk and no effect on cognitive function. Few studies limit the recommendations regarding oral anticoagulants and vitamin K inhibitors as preventive measures 75,88,89 .

VCI is a highly heterogeneous disease. Recent evidence has helped us improve our understanding of how cerebrovascular disease contributes to cognitive impairment.

More research is needed to explain the relationship between VCI and neurodegenerative disease. Preventing vascular injury by treating modifiable risk factors remains a cornerstone in the fight against cognitive impairment. More studies are needed to develop symptomatic and disease-modifying treatments.

Funding: none.

This study was conducted by Neurology Department, Hospital Civil Fray Antonio Alcalde. Guadalajara, Mexico.
==== Refs
REFERENCES

1 Hachinski V Brain health: the time has come Eur J Neurol 2022 29 9 2553 2554 10.1111/ene.15414 35599629
2 Khera T Rangasamy V Cognition and pain: a review Front Psychol 2021 12 673962 673962 10.3389/fpsyg.2021.673962 34093370
3 Sanford AM Mild cognitive impairment Clin Geriatr Med 2017 33 3 325 337 10.1016/j.cger.2017.02.005 28689566
4 American Psychiatric Association Diagnostic and statistical manual of mental disorders 5th ed Philadelphia American Psychiatric Association 2013
5 Skrobot OA O’Brien J Black S Chen C DeCarli C Erkinjuntti T The vascular impairment of cognition classification consensus study Alzheimers Dement 2017 13 6 624 633 10.1016/j.jalz.2016.10.007 27960092
6 van der Flier WM Skoog I Schneider JA Pantoni L Mok V Chen CLH Vascular cognitive impairment Nat Rev Dis Primer 2018 4 18003 18003 10.1038/nrdp.2018.3
7 Skrobot OA Black SE Chen C DeCarli C Erkinjuntti T Ford GA Progress toward standardized diagnosis of vascular cognitive impairment: Guidelines from the Vascular Impairment of Cognition Classification Consensus Study Alzheimers Dement 2018 14 3 280 292 10.1016/j.jalz.2017.09.007 29055812
8 Petersen RC Lopez O Armstrong MJ Getchius TSD Ganguli M Gloss D Practice guideline update summary: Mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology Neurology 2018 90 3 126 135 10.1212/WNL.0000000000004826 29282327
9 Gauthier S Reisberg B Zaudig M Petersen RC Ritchie K Broich K Mild cognitive impairment Lancet 2006 367 9518 1262 1270 10.1016/S0140-6736(06)68542-5 16631882
10 Arce Rentería M Manly JJ Vonk JMJ Mejia Arango S Michaels Obregon A Samper-Ternent R Midlife vascular factors and prevalence of mild cognitive impairment in late-life in Mexico J Int Neuropsychol Soc 2022 28 4 351 361 10.1017/S1355617721000539 34376262
11 Ribeiro FS Teixeira-Santos AC Leist AK The prevalence of mild cognitive impairment in Latin America and the Caribbean: a systematic review and meta-analysis Aging Ment Health 2022 26 9 1710 1720 10.1080/13607863.2021.2003297 34844480
12 Ribeiro F Teixeira-Santos AC Caramelli P Leist AK Prevalence of dementia in Latin America and Caribbean countries: systematic review and meta-analyses exploring age, sex, rurality, and education as possible determinants Ageing Res Rev 2022 81 101703 101703 10.1016/j.arr.2022.101703 35931410
13 Patterson C World Alzheimer report 2018 London Alzheimer's Disease International 2018
14 César KG Brucki SMD Takada LT Nascimento LFC Gomes CMS Almeida MCS Prevalence of cognitive impairment without dementia and dementia in Tremembé, Brazil Alzheimer Dis Assoc Disord 2016 30 3 264 271 10.1097/WAD.0000000000000122 26629676
15 Melo SC Champs APS Goulart RF Malta DC Passos VMA Dementias in Brazil: increasing burden in the 2000-2016 period. Estimates from the Global Burden of Disease Study 2016 Arq Neuropsiquiatr 2020 78 12 762 771 10.1590/0004-282X20200059 33295419
16 Juarez-Cedillo T Gonzelez-Figueroa E Gutierez-Gutierez L Aguilar-Navarro SG Garcia-Cruz JC Escobedo de la Peña J Prevalence of dementia and main subtypes in Mexico: the study on aging and dementia in Mexico (SADEM) J Alzheimers Dis 2022 89 3 931 941 10.3233/JAD-220012 35964177
17 Boyle PA Yu L Wilson RS Leurgans SE Schneider JA Bennett DA Person-specific contribution of neuropathologies to cognitive loss in old age Ann Neurol 2018 83 1 74 83 10.1002/ana.25123 29244218
18 Arauz A Alonso E Rodríguez-Saldaña J Reynoso-Marenco M Benitez IT Mayorga AM Cognitive impairment and mortality in older healthy Mexican subjects: a population-based 10-year follow-up study Neurol Res 2005 27 8 882 886 10.1179/016164105X49427 16354550
19 Soto-Añari M Camargo L Ramos-Henderson M Rivera-Fernández C Denegri-Solís L Calle U Prevalence of dementia and associated factors among older adults in Latin America during the COVID-19 pandemic Dement Geriatr Cogn Dis Extra 2021 11 3 213 221 10.1159/000518922 34721498
20 Calandri IL Livingston G Paradela R Ossenkoppele R Crivelli L Allegri RF Sex and socioeconomic disparities in dementia risk: a population attributable fractions analysis in Argentina Neuroepidemiology 2024 10.1159/000536524
21 Molero AE Pino-Ramírez G Maestre GE High prevalence of dementia in a Caribbean population Neuroepidemiology 2007 29 1-2 107 112 10.1159/000109824 17940342
22 Oveisgharan S Dawe RJ Yu L Kapasi A Arfanakis K Hachinski V Frequency and underlying pathology of pure vascular cognitive impairment JAMA Neurol 2022 79 12 1277 1286 10.1001/jamaneurol.2022.3472 36279115
23 Pollock A St George B Fenton M Firkins L Top 10 research priorities relating to life after stroke--consensus from stroke survivors, caregivers, and health professionals Int J Stroke 2014 9 3 313 320 10.1111/j.1747-4949.2012.00942.x 23227818
24 Barbay M Taillia H Nédélec-Ciceri C Bompaire F Bonnin C Varvat J Prevalence of poststroke neurocognitive disorders using National Institute of Neurological Disorders and Stroke-Canadian Stroke Network, VASCOG Criteria (Vascular Behavioral and Cognitive Disorders), and Optimized Criteria of Cognitive Deficit Stroke 2018 49 5 1141 1147 10.1161/STROKEAHA.117.018889 29643258
25 Pendlebury ST Rothwell PM Oxford Vascular Study Incidence and prevalence of dementia associated with transient ischaemic attack and stroke: analysis of the population-based Oxford Vascular Study Lancet Neurol 2019 18 3 248 258 10.1016/S1474-4422(18)30442-3 30784556
26 Arauz A Rodríguez-Agudelo Y Sosa AL Chávez M Paz F González M Vascular cognitive disorders and depression after first-ever stroke: the Fogarty-Mexico stroke cohort Cerebrovasc Dis 2014 38 4 284 289 10.1159/000366471 25412708
27 Brucki SMD Machado MF Rocha MSG Vascular Cognitive Impairment (VCI) after non-embolic ischemic stroke during a 12-month follow-up in Brazil Dement Neuropsychol 2012 6 3 164 169 10.1590/S1980-57642012DN06030009 29213791
28 Iwagami M Qizilbash N Gregson J Douglas I Johnson M Pearce N Blood cholesterol and risk of dementia in more than 1·8 million people over two decades: a retrospective cohort study Lancet Healthy Longev 2021 2 8 e498 e506 10.1016/S2666-7568(21)00150-1 36097999
29 Yeverino-Castro SG Mejía-Arango S Mimenza-Alvarado AJ Cantú-Brito C Avila-Funes JA Aguilar-Navarro SG Prevalence and incidence of possible vascular dementia among Mexican older adults: analysis of the Mexican Health and Aging Study PLoS One 2021 16 7 e0253856 10.1371/journal.pone.0253856 34237081
30 Del Brutto OH Mera RM Recalde BY Rumbea DA Del Brutto VJ High social risk influence progression of white matter hyperintensities of presumed vascular origin: a prospective study in community-dwelling older adults Stroke 2022 53 8 2577 2584 10.1161/STROKEAHA.122.038561 35506386
31 Pendlebury ST Rothwell PM Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis Lancet Neurol 2009 8 11 1006 1018 10.1016/S1474-4422(09)70236-4 19782001
32 Mok VCT Lam BYK Wong A Ko H Markus HS Wong LK Early-onset and delayed-onset poststroke dementia – revisiting the mechanisms Nat Rev Neurol 2017 13 3 148 159 10.1038/nrneurol.2017.16 28211452
33 Livingston G Huntley J Sommerlad A Ames D Ballard C Banerjee S Dementia prevention, intervention, and care: 2020 report of the Lancet Commission Lancet 2020 396 10248 413 446 10.1016/S0140-6736(20)30367-6 32738937
34 Sposato LA Kapral MK Fang J Gill SS Hackam DG Cipriano LE Declining incidence of stroke and dementia: coincidence or prevention opportunity? JAMA Neurol 2015 72 12 1529 1531 10.1001/jamaneurol.2015.2816 26658969
35 Libon DJ Price CC Heilman KM Grossman M Alzheimer's "other dementia" Cogn Behav Neurol 2006 19 2 112 116 10.1097/01.wnn.0000209870.69522.a3 16783135
36 Zlokovic BV The blood-brain barrier in health and chronic neurodegenerative disorders Neuron 2008 57 2 178 201 10.1016/j.neuron.2008.01.003 18215617
37 Skrobot OA Attems J Esiri M Hortobágyi T Ironside JW Kalaria RN Vascular cognitive impairment neuropathology guidelines (VCING): the contribution of cerebrovascular pathology to cognitive impairment Brain 2016 139 11 2957 2969 10.1093/brain/aww214 27591113
38 Makin SDJ Turpin S Dennis MS Wardlaw JM Cognitive impairment after lacunar stroke: systematic review and meta-analysis of incidence, prevalence and comparison with other stroke subtypes J Neurol Neurosurg Psychiatry 2013 84 8 893 900 10.1136/jnnp-2012-303645 23457225
39 Litak J Mazurek M Kulesza B Szmygin P Litak J Kamieniak P Cerebral small vessel disease Int J Mol Sci 2020 21 24 9729 9729 10.3390/ijms21249729 33419271
40 Chabriat H Oberstein SL Cognition, mood and behavior in CADASIL Cereb Circ Cogn Behav 2022 3 100043 100043 10.1016/j.cccb.2022.100043 36324403
41 Locatelli M Padovani A Pezzini A Pathophysiological mechanisms and potential therapeutic targets in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) Front Pharmacol 2020 11 321 321 10.3389/fphar.2020.00321 32231578
42 Aguilar-Navarro SG Mimenza-Alvarado AJ Anaya-Escamilla A Gutiérrez-Robledo LM Frailty and vascular cognitive impairment: mechanisms behind the link Rev Investig Clin 2016 68 1 25 32 27028174
43 Schneider JA Wilson RS Cochran EJ Bienias JL Arnold SE Evans DA Relation of cerebral infarctions to dementia and cognitive function in older persons Neurology 2003 60 7 1082 1088 10.1212/01.wnl.0000055863.87435.b2 12682310
44 Tatemichi TK Desmond DW Mayeux R Paik M Stern Y Sano M Dementia after stroke: baseline frequency, risks, and clinical features in a hospitalized cohort Neurology 1992 42 6 1185 1193 10.1212/wnl.42.6.1185 1603346
45 Mijajlović MD Pavlović A Brainin M Heiss WD Quinn TJ Ihle-Hansen HB Post-stroke dementia – a comprehensive review BMC Med 2017 15 1 11 11 10.1186/s12916-017-0779-7 28095900
46 Allan LM Rowan EN Firbank MJ Thomas AJ Parry SW Polvikoski TM Long term incidence of dementia, predictors of mortality and pathological diagnosis in older stroke survivors Brain 2011 134 Pt 12 3716 3727 10.1093/brain/awr273 22171356
47 Dufouil C Godin O Chalmers J Coskun O MacMahon S Tzourio-Mazoyer N Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history Stroke 2009 40 6 2219 2221 10.1161/STROKEAHA.108.540633 19390070
48 Li L Zhang X Yang D Luo G Chen S Le W Hypoxia increases Abeta generation by altering beta- and gamma-cleavage of APP Neurobiol Aging 2009 30 7 1091 1098 10.1016/j.neurobiolaging.2007.10.011 18063223
49 Iadecola C The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia Acta Neuropathol 2010 120 3 287 296 10.1007/s00401-010-0718-6 20623294
50 Sweeney MD Kisler K Montagne A Toga AW Zlokovic BV The role of brain vasculature in neurodegenerative disorders Nat Neurosci 2018 21 10 1318 1331 10.1038/s41593-018-0234-x 30250261
51 Sweeney MD Montagne A Sagare AP Nation DA Schneider LS Chui HC Vascular dysfunction-the disregarded partner of Alzheimer's disease Alzheimers Dement 2019 15 1 158 167 10.1016/j.jalz.2018.07.222 30642436
52 Bakker ENTP Bacskai BJ Arbel-Ornath M Aldea R Bedussi B Morris AWJ Lymphatic clearance of the brain: perivascular, paravascular and significance for neurodegenerative diseases Cell Mol Neurobiol 2016 36 2 181 194 10.1007/s10571-015-0273-8 26993512
53 Kalaria RN Ihara M Medial temporal lobe atrophy is the norm in cerebrovascular dementias Eur J Neurol 2017 24 4 539 540 10.1111/ene.13243 28191732
54 Hachinski VC Lassen NA Marshall J Multi-infarct dementia A cause of mental deterioration in the elderly. Lancet 1974 2 7874 207 210 10.1016/s0140-6736(74)91496-2 4135618
55 Román GC Tatemichi TK Erkinjuntti T Cummings JL Masdeu JC Garcia JH Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop Neurology 1993 43 2 250 260 10.1212/wnl.43.2.250 8094895
56 Erkinjuntti T Clinical criteria for vascular dementia: the NINDS-AIREN criteria Dementia 1994 5 3-4 189 192 10.1159/000106721 8087178
57 Bowler JV Hachinski V Vascular cognitive impairment: a new approach to vascular dementia Baillieres Clin Neurol 1995 4 2 357 376 7496625
58 Shim HS Vascular cognitive impairment and post-stroke cognitive deficits Curr Neurol Neurosci Rep 2014 14 1 418 418 10.1007/s11910-013-0418-4 24272272
59 Gorelick PB Scuteri A Black SE Decarli C Greenberg SM Iadecola C Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association Stroke 2011 42 9 2672 2713 10.1161/STR.0b013e3182299496 21778438
60 Sachdev P Kalaria R O’Brien J Skoog I Alladi S Black SE Diagnostic criteria for vascular cognitive disorders: a VASCOG statement Alzheimer Dis Assoc Disord 2014 28 3 206 218 10.1097/WAD.0000000000000034 24632990
61 Sachdev PS Lipnicki DM Crawford JD Brodaty H The vascular behavioral and cognitive disorders criteria for vascular cognitive disorders: a validation study Eur J Neurol 2019 26 9 1161 1167 10.1111/ene.13960 30927497
62 Barbosa BJAP Siqueira JI Alves GS Sudo FK Suemoto CK Tovar-Moll F Diagnosis of vascular cognitive impairment: recommendations of the scientific department of cognitive neurology and aging of the Brazilian Academy of Neurology Dement Neuropsychol 2022 16 3 Suppl 1 53 72 10.1590/1980-5764-DN-2022-S104PT 36533159
63 Hachinski VC Bowler JV Vascular dementia Neurology 1993 43 10 2159 2160 author reply 2160-1. 10.1212/wnl.43.10.2159-a
64 Hachinski V Iadecola C Petersen RC Breteler MM Nyenhuis DL Black SE National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards Stroke 2006 37 9 2220 2241 10.1161/01.STR.0000237236.88823.47 16917086
65 Godefroy O Leclercq C Roussel M Moroni C Quaglino V Beaunieux H French adaptation of the vascular cognitive impairment harmonization standards: the GRECOG-VASC study Int J Stroke 2012 7 4 362 363 10.1111/j.1747-4949.2012.00794.x 22583525
66 Dong Y Xu J Chan BPL Seet RCS Venketasubramanian N Teoh HL The Montreal Cognitive Assessment is superior to National Institute of Neurological Disease and Stroke-Canadian Stroke Network 5-minute protocol in predicting vascular cognitive impairment at 1 year BMC Neurol 2016 16 46 46 10.1186/s12883-016-0570-y 27067253
67 Ghafar MZAA Miptah HN O’Caoimh R Cognitive screening instruments to identify vascular cognitive impairment: a systematic review Int J Geriatr Psychiatry 2019 34 8 1114 1127 10.1002/gps.5136 31050033
68 Alber J Alladi S Bae H Barton DA Beckett LA Bell JM White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): knowledge gaps and opportunities Alzheimers Dement (N Y) 2019 5 1 107 117 10.1016/j.trci.2019.02.001 31011621
69 Cheon DY Han KD Kim CH Oh MS Lee BC Kim Y Association between exercise habit changes and incident dementia after ischemic stroke Sci Rep 2023 13 1 3959 3959 10.1038/s41598-023-31229-z 36894695
70 Espeland MA Erickson K Neiberg RH Jakicic JM Wadden TA Wing RR Brain and white matter hyperintensity volumes after 10 years of random assignment to lifestyle intervention Diabetes Care 2016 39 5 764 771 10.2337/dc15-2230 27208378
71 Battle CE Abdul-Rahim AH Shenkin SD Hewitt J Quinn TJ Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis Cochrane Database Syst Rev 2021 2 2 CD013306 CD013306 10.1002/14651858.CD013306.pub2 33704781
72 Moretti R Torre P Antonello RM Cazzato G Bava A Rivastigmine in subcortical vascular dementia: a randomized, controlled, open 12-month study in 208 patients Am J Alzheimers Dis Other Demen 2003 18 5 265 272 10.1177/153331750301800508 14569643
73 Wilcock G Möbius HJ Stöffler A MMM 500 group A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500) Int Clin Psychopharmacol 2002 17 6 297 305 10.1097/00004850-200211000-00005 12409683
74 Walsh AC Anticoagulant therapy as a potentially effective method for the prevention of presenile dementia: two case reports J Am Geriatr Soc 1968 16 4 472 481 10.1111/j.1532-5415.1968.tb02829.x 4171324
75 Mongkhon P Naser AY Fanning L Tse G Lau WCY Wong ICK Oral anticoagulants and risk of dementia: a systematic review and meta-analysis of observational studies and randomized controlled trials Neurosci Biobehav Rev 2019 96 1 9 10.1016/j.neubiorev.2018.10.025 30391408
76 Harrison SL Buckley BJR Ritchie LA Proietti R Underhill P Lane DA Oral anticoagulants and outcomes in adults ≥80 years with atrial fibrillation: a global federated health network analysis J Am Geriatr Soc 2022 70 8 2386 2392 10.1111/jgs.17884 35587227
77 Bezabhe WM Bereznicki LR Radford J Wimmer BC Salahudeen MS Garrahy E Oral anticoagulant treatment and the risk of dementia in patients with atrial fibrillation: a population-based cohort study J Am Heart Assoc 2022 11 7 e023098 10.1161/JAHA.121.023098 35301852
78 Caramelli B Yu PC Cardozo FAM Magalhães IR Spera RR Amado DK Effects of dabigatran versus warfarin on 2-year cognitive outcomes in old patients with atrial fibrillation: results from the GIRAF randomized clinical trial BMC Med 2022 20 1 374 374 10.1186/s12916-022-02563-2 36284318
79 Kernan WN Ovbiagele B Black HR Bravata DM Chimowitz MI Ezekowitz MD Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association Stroke 2014 45 7 2160 2236 10.1161/STR.0000000000000024 24788967
80 Tang Y Xing Y Zhu Z He Y Li F Yang J The effects of 7-week cognitive training in patients with vascular cognitive impairment, no dementia (the Cog-VACCINE study): a randomized controlled trial Alzheimers Dement 2019 15 5 605 614 10.1016/j.jalz.2019.01.009 30894299
81 Pantoni L Poggesi A Diciotti S Valenti R Orsolini S Della Rocca E Effect of attention training in mild cognitive impairment patients with subcortical vascular changes: the RehAtt study J Alzheimers Dis 2017 60 2 615 624 10.3233/JAD-170428 28869475
82 Hachinski V Einhäupl K Ganten D Alladi S Brayne C Stephan BCM Preventing dementia by preventing stroke: the Berlin Manifesto Alzheimers Dement 2019 15 7 961 984 10.1016/j.jalz.2019.06.001 31327392
83 Cerasuolo JO Mandzia J Cipriano LE Kapral MK Fang J Hachinski V Intravenous thrombolysis after first-ever ischemic stroke and reduced incident dementia rate Stroke 2022 53 4 1170 1177 10.1161/STROKEAHA.121.034969 34965738
84 Chang Wong E Chang Chui H Vascular cognitive impairment and dementia Continuum (Minneap Minn) 2022 28 3 750 780 10.1212/CON.0000000000001124 35678401
85 Thacker EL Gillett SR Wadley VG Unverzagt FW Judd SE McClure LA The American Heart Association Life's Simple 7 and incident cognitive impairment: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study J Am Heart Assoc 2014 3 3 e000635 10.1161/JAHA.113.000635 24919926
86 SPRINT MIND Investigators for the SPRINT Research Group Williamson JD Pajewski NM Auchus AP Bryan RN Chelune G Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial JAMA 2019 321 6 553 561 10.1001/jama.2018.21442 30688979
87 Ngandu T Lehtisalo J Solomon A Levälahti E Ahtiluoto S Antikainen R A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial Lancet 2015 385 9984 2255 2263 10.1016/S0140-6736(15)60461-5 25771249
88 Bunch TJ May H Cutler M Woller SC Jacobs V Stevens SM Impact of anticoagulation therapy on the cognitive decline and dementia in patients with non-valvular atrial fibrillation (cognitive decline and dementia in patients with non-valvular atrial fibrillation [CAF] trial) J Arrhythm 2022 38 6 997 1008 10.1002/joa3.12781 36524040
89 Kwan J Hafdi M Chiang LLW Myint PK Wong LS Quinn TJ Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia Cochrane Database Syst Rev 2022 7 CD012269 CD012269 10.1002/14651858.CD012269.pub2 35833913
